Taskforce updates molnupiravir guidance following PANORAMIC trial results
2 December, 2022
The Taskforce has incorporated the preliminary results of the PANORAMIC trial into the body of evidence for oral antiviral molnupiravir (Lagevrio). This large (25,783 participants) open-label randomised controlled trial was conducted in the UK, in patients who had multiple SARS-CoV-2 vaccine doses, during the Omicron wave, comparing molnupiravir to standard care. The Taskforce Drug Treatments Panel, Care of Older People...
